hla restriction

Peptide Clinical Trials: What Influenza HA Research Teaches Us

Peptide clinical trial design depends on well-characterized epitopes and reliable validation. Influenza Hemagglutinin (HA) research offers a clear model: promiscuous CD4+ epitopes like HA 306-318 (HA 322-334) bind across multiple HLA-DR alleles, making them benchmark positive controls for recall responses, TCR kinetics, and universal flu vaccine candidates. Here is how to read that evidence and verify peptide quality before it enters any translational study.